Trial · NCT03152552
Outcomes26
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 26
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 12 | Baseline, Week 12 | The Full Analysis Set (FAS) consisted of all randomized patients who were not mis-randomized. LIK066 doses and placebo arms are considered per study primary objective. | ratio | GEOMETRIC_MEAN |
| SECONDARY | Change From Baseline in Glycated Hemoglobin (HbA1c) at Weeks 12 and 36 | Baseline, Week 12, Week 36 | The Full Analysis Set (FAS) consisted of all randomized patients who were not mis-randomized. | Percentage (%) | MEAN |
| SECONDARY | Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 12 and 36 | Baseline, Week 12, Week 36 | The Full Analysis Set (FAS) consisted of all randomized patients who were not mis-randomized. | millimoles per litre (mmol/L) | MEAN |
| SECONDARY | Change From Baseline in Body Weight at Weeks 12 and 36 | Baseline, Week 12, Week 36 | The Full Analysis Set (FAS) consisted of all randomized patients who were not mis-randomized. | kilogram (kg) | MEAN |
| SECONDARY | Change From Baseline in Body Composition Assessed by Bio-impedance (Total Body Fat Mass) at Weeks 12 and 36 | Baseline, Week 12, Week 36 | The Full Analysis Set (FAS) consisted of all randomized patients who were not mis-randomized. | Percentage of body fat mass | MEAN |
| SECONDARY | Change From Baseline in Body Composition Assessed by Bio-impedance (Visceral Fat Level) at Weeks 12 and 36 | Baseline, Week 12, Week 36 | The Full Analysis Set (FAS) consisted of all randomized patients who were not mis-randomized. | Level | MEAN |
| SECONDARY | Change From Baseline in Body Composition Assessed by Bio-impedance (Lean Body Mass) at Weeks 12 and 36 | Baseline, Week 12, Week 36 | The Full Analysis Set (FAS) consisted of all randomized patients who were not mis-randomized. | Percentage of body fat mass | MEAN |
| SECONDARY | Change From Baseline in Body Composition Assessed by DXA (Total Body Fat Mass) at Weeks 12 and 36 | Baseline, Week 12, Week 36 | The Full Analysis Set (FAS) consisted of all randomized patients who were not mis-randomized. The analysis included patients who participated in the DXA sub-study. Due to early termination of the study, only the data shown was available. | kilogram (kg) | MEAN |
| SECONDARY | Change From Baseline in Body Composition Assessed by DXA (Visceral Fat Mass) at Weeks 12 and 36 | Baseline, Week 12, Week 36 | The Full Analysis Set (FAS) consisted of all randomized patients who were not mis-randomized. The analysis included patients who participated in the DXA sub-study. Due to early termination of the study, no data was collected. | ||
| SECONDARY | Change From Baseline in Body Composition Assessed by DXA (Lean Body Mass) at Weeks 12 and 36 | Baseline, Week 12, Week 36 | The Full Analysis Set (FAS) consisted of all randomized patients who were not mis-randomized. The analysis included patients who participated in the DXA sub-study. Due to early termination of the study, only the data shown was available. | kilogram (kg) | MEAN |
| SECONDARY | Change From Baseline in Body Composition Assessed by DXA (Total Body Water) at Weeks 12 and 36 | Baseline, Week 12, Week 36 | FAS consisted of all randomized patients who were not mis-randomized. Analysis included patients who participated in the DXA sub-study. Due to early termination of the study, no data was collected. | ||
| SECONDARY | Change From Baseline in Sitting Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Weeks 12 and 36 | Baseline, Week 12, Week 36 | The Full Analysis Set (FAS) consisted of all randomized patients who were not mis-randomized. Due to early termination of the study, only the data shown was available. | millimeter of mercury (mmHg) | MEAN |
| SECONDARY | Change From Baseline in Fasting Lipid Profile (Triglycerides (TG)) at Weeks 12 and 36 | Baseline, Week 12, Week 36 | The Full Analysis Set (FAS) consisted of all randomized patients who were not mis-randomized. Due to early termination of the study, only the data shown was available. | Percent change | MEAN |
| SECONDARY | Change From Baseline in Fasting Lipid Profile (Lipoproteins) at Weeks 12 and 36 | Baseline, Week 12, Week 36 | The Full Analysis Set (FAS) consisted of all randomized patients who were not mis-randomized. Due to early termination of the study, only the data shown was available. | Percent change | MEAN |
| SECONDARY | Change From Baseline in Fasting Lipid Profile (Total Cholesterol) at Weeks 12 and 36 | Baseline, Week 12, Week 36 | FAS consisted of all randomized patients who were not mis-randomized. Analysis included patients who participated in the study. Due to early termination of the study, only the data shown was available. 'Overall Number of Participants Analyzed' = enrolled in the study. 'Number Analyzed' = number of participants with data available. | Percent change | MEAN |
| SECONDARY | Change From Baseline in High Sensitive C-reactive Protein (hsCRP) at Weeks 12 and 36 | Baseline, Week 12, Week 36 | The Full Analysis Set (FAS) consisted of all randomized patients who were not mis-randomized. Due to early termination of the study, only the data shown was available. | milligram per litre (mg/L) | GEOMETRIC_MEAN |
| SECONDARY | Change From Baseline in 24 Hour Urinary Glucose Excretion (UGE) at Weeks 12 and 36 | Baseline, Week 12, Week 36 | FAS consisted of all randomized patients who were not mis-randomized. Due to early termination of the study, only the data shown was available. 'Overall Number of Participants Analyzed' = enrolled in the 24 hour urine collection sub-study. 'Number Analyzed' = number of participants with data available. | millimoles per 24 hours (mmol/24h) | MEAN |
| SECONDARY | Change From Baseline in 24 Hour Sodium Excretion at Weeks 12 and 36 | Baseline, Week 12, Week 36 | FAS consisted of all randomized patients who were not mis-randomized. Due to early termination of the study, only the data shown was available. 'Overall Number of Participants Analyzed' = enrolled in the 24 hour urine collection sub-study. 'Number Analyzed' = number of participants with data available. | millimoles per 24 hours (mmol/24h) | MEAN |
| SECONDARY | Change From Baseline in Left Atrial Size at Weeks 12 and 36 | Baseline, Week 12, Week 36 | The Full Analysis Set (FAS) consisted of all randomized patients who were not mis-randomized. LIK066 doses and placebo arms were considered per study objective. Due to early termination of the study, only the data shown was available. | milliliter per square meter (mL/m^2) | MEAN |
| SECONDARY | Change From Baseline in Left Atrial Volume at Weeks 12 and 36 | Baseline, Week 12, Week 36 | The Full Analysis Set (FAS) consisted of all randomized patients who were not mis-randomized. LIK066 doses and placebo arms were considered per study objective. Due to early termination of the study, only the data shown was available. | milliliter (mL) | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03152552/outcomes